User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Name Symbol Market Type
AstraZeneca PLC NASDAQ:AZN NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.41 0.77% 53.89 53.88 53.89 53.90 53.53 53.53 757,759 15:03:16

AstraZeneca's Farxiga Gets U.S. FDA Approval as Chronic-Kidney-Disease Treatment

04/05/2021 7:48am

Dow Jones News

AstraZeneca (NASDAQ:AZN)
Historical Stock Chart

From Apr 2021 to May 2021

Click Here for more AstraZeneca Charts.

By Anthony O. Goriainoff


AstraZeneca PLC said Tuesday that the U.S. Food and Drug Administration approved Farxiga for the treatment of chronic kidney disease in patients at risk of progression with, and without, Type 2 diabetes.

The London-listed pharmaceutical company said the sodium-glucose cotransporter 2 inhibitor's approval was based on positive results from the DAPA-CKD Phase III trial.

The company said Farxiga will be used to decrease the risk of end-stage kidney disease, cardiovascular death, as well as hospitalization for heart failure in adults with chronic kidney disease at risk of progression, among others.


Write to Anthony O. Goriainoff at


(END) Dow Jones Newswires

May 04, 2021 02:33 ET (06:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year AstraZeneca Chart

1 Year AstraZeneca Chart

1 Month AstraZeneca Chart

1 Month AstraZeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210507 14:18:21